Skip to content
Home/Companies/Biotech/Engimmune Therapeutics

Engimmune Therapeutics

Biotech·Switzerland·Active·4yr hold
Entry
2022
Hold
4yr
Status
Active

Who owns Engimmune Therapeutics?

Engimmune Therapeutics is a Swiss Biotech company, currently owned by Novo Holdings since 2022.

Hand-verified · updated 2026-08-18

Open JSON · CC-BY
Novo Holdings
Investor
Novo Holdings
Novo Holdings Seed Investments · 1999 · VC

Key facts

HQSwitzerland
SectorBiotech
StatusActive

More from Novo Holdings Seed Investments

Other portfolio companies in the same fund.

cAMPfield
Active
BiotechUS· 2026
Coultreon Biopharma
Active
BiotechUS· 2026
QuantumCell
Active
BiotechDenmark· 2025
Booster Therapeutics
Active
BiotechGermany· 2024
Orbis Medicines
Active
BiotechDenmark· 2024
RheumaLogics
Active
BiotechDenmark· 2024

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Engimmune Therapeutics?

Engimmune Therapeutics is currently owned by Novo Holdings, through Novo Holdings Seed Investments, since 2022.

When did Novo Holdings acquire Engimmune Therapeutics?

Novo Holdings acquired Engimmune Therapeutics in 2022.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue